Healthcare Review: Cytori Therapeutics, Centene Corp, Alexza Pharmaceuticals, Celsion Corporation, Merck & Co Are Big Movers |
![]() |
![]() |
By Staff and Wire Reports |
Friday, 14 December 2012 14:54 |
Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) shares declined 15.36% to $2.81 in the morning hour after the company announced the sale of 7,020,000 shares of its common stock in an underwritten public offering at a price to the public of $2.85 per share. The net offering proceeds to Cytori from the sale of the shares are expected to be approximately $18.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses, but excluding any exercise of the underwriters` over-allotment option. CYTX anticipates using the net proceeds from this offering for general corporate purposes. Full year 2012 earnings will be reported on February 5, 2013, at 6:00 AM, with the conference call at 8:30 AM (Eastern Time). The company will host an investor meeting, including a question-and-answer session, to discuss the details of its guidance. ThermoDox is currently being evaluated under a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA) in a global, multi-center, randomized, pivotal Phase III trial (the HEAT Study) in patients with non-resectable primary liver cancer. "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |